Cingulate Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CING research report →
Range $10 – $10
Price Chart
About the company
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine).
- CEO
- Shane J. Schaffer
- IPO
- 2021
- Employees
- 14
- HQ
- Kansas City, KS, US
Get TickerSpark's AI analysis on CING
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $71.79M
- P/E
- -1.22
- Fwd P/E
- 8.08
- PEG
- -0.06
- P/S
- 0.00
- P/B
- 2.99
- EV/EBITDA
- -139.43
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -238.41%
- ROIC
- -0.07%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-19,938,108
- Net Income
- $-22,449,911-35.6%
- EPS
- $-4.13+59.5%
- OCF Growth
- +6.5%
- FCF Growth
- +6.7%
- 52W High
- $11.89
- 52W Low
- $3.16
- 50D MA
- $4.94
- 200D MA
- $5.18
- Beta
- -0.91
- RSI (14)
- 61
- Avg Volume
- 427.89K
No earnings-call transcripts are available for CING yet.
- Free Float
- 95.2%
- Shares Outstanding
- 13.47M
- Float Shares
- 12.82M
of shares held by institutions
18 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 151.43K | ▲ 77.64K |
Held by 23 ETFs
Biggest fund positions in CING by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 16, 26 | Schaffer Shane J. | other | 197,650 |
| Jul 16, 26 | Schaffer Shane J. | other | 97,350 |
| Jul 16, 26 | Downey Bryan Wade | other | 67,000 |
| Jul 16, 26 | Downey Bryan Wade | other | 33,000 |
| Jul 16, 26 | Lawrence Bryan Jay | other | 20,000 |
| Jul 16, 26 | Brams Matthew | other | 53,600 |
| Jul 16, 26 | Brams Matthew | other | 26,400 |
| Jul 16, 26 | Hargroves Thomas Jeffrey | other | 20,000 |
| Jul 16, 26 | Callahan Jennifer L. | other | 40,200 |
| Jul 16, 26 | Callahan Jennifer L. | other | 19,800 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CING coverage
Recent articles, reports, and earnings notes.
No research on CING yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CING report →Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness
globenewswire.com · Aug 13
Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301's Differentiated Pharmacokinetic Profile
globenewswire.com · Aug 11
Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology
globenewswire.com · Jul 30
Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®
globenewswire.com · Jul 2
Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301
globenewswire.com · Jun 16
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26
newsfilecorp.com · Jun 4
US FDA declines to approve Cingulate's ADHD drug
reuters.com · Jun 2
Cingulate Receives Complete Response Letter from FDA for CTx-1301
globenewswire.com · Jun 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.